GW Pharmaceuticals misses by $0.01, beats on revenue

GW Pharmaceuticals (GWPH): FQ2 EPS of -$0.04 misses by $0.01.

Revenue of $12.55M beats by $0.07M.

From other sites
Comments (3)
  • danr66
    , contributor
    Comments (23) | Send Message
    IND status from FDA for phase 2/3 clinical trials of Epidiolex announced this a.m.
    7 May 2014, 07:29 AM Reply Like
  • Dayadog
    , contributor
    Comments (5) | Send Message
    This was a beat on EPS, you have your numbers off?
    7 May 2014, 08:10 AM Reply Like
  • Rich Knot
    , contributor
    Comments (2) | Send Message
    This Company are to be congratulated on their listing on Nasdaq.Their revenue figures are irrelevant as far as a valuation is concerned.It is quite possible that GWPharmaceuticals will become one of the largest pharmaceutical companies in the World within the next ten years.
    7 May 2014, 08:10 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs